6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jan 31 07:16 ET

6-K: Novartis Intrathecal Onasemnogene Abeparvovec Phase Iii Study Meets Primary Endpoint in Children and Young Adults with SMA

Dec 30, 2024 06:10 ET

6-K: Novartis Scemblix® FDA Approved in Newly Diagnosed CML

Oct 29, 2024 16:11 ET

6-K: FDA Approves Novartis Kisqali® to Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

Sep 17, 2024 14:09 ET

6-K: Novartis Receives FDA Accelerated Approval for Fabhalta®

Aug 8, 2024 16:30 ET

Novartis AG | S-8 POS: S-8 POS

Feb 15, 2024 16:20 ET

Novartis AG | 6-K: Annual Report 2023 and Novartis in Society - Integrated Report 2023

Jan 31, 2024 07:46 ET

Novartis AG | 6-K: Novartis Scemblix® Shows Superior Major Molecular Response (Mmr) Rates Vs. Standard-of-Care Tkis in Phase Iii Trial for Newly Diagnosed Patients with Chronic Myeloid Leukemia

Jan 8, 2024 00:00 ET

Novartis AG | 6-K: Novartis Investigational Iptacopan Phase Iii Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3g)

Dec 11, 2023 06:05 ET

Novartis AG | 6-K: Novartis Receives Fda Approval for Fabhalta® (Iptacopan)

Dec 5, 2023 20:19 ET

Novartis AG | 6-K: Novartis Upgrades Mid-Term Sales Growth Guidance, Showcases Its Differentiated Innovative Medicines Strategy and Robust Pipeline at R&d Day

Nov 28, 2023 06:10 ET

Novartis AG | 6-K: Report of Foreign Private Issuer

Oct 30, 2023 06:05 ET

Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 4, 2023 06:57 ET

Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 2, 2023 06:05 ET

Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Aug 9, 2023 06:05 ET

Novartis AG | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

Jul 10, 2023 16:08 ET

Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jul 10, 2023 06:06 ET

Novartis AG | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

Jun 12, 2023 09:41 ET

Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 12, 2023 09:26 ET

Novartis AG | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

Mar 27, 2023 08:14 ET